Systematic review and meta-analysis of the efficacy and hypoglycemic safety of gliclazide versus other insulinotropic agents

Diabetes Research and Clinical Practice

Volumn 110, Issue 1, 2015, Pages 75-81

  Chan, Siew Pheng ^a   Colagiuri, Stephen ^b  

^a UNIVERSITY OF MALAYA   (Malaysia)

^b UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Efficacy; Gliclazide; Hypoglycemia; Insulinotropic; Meta analysis; Systematic review

Indexed keywords

DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLIBENCLAMIDE; GLICLAZIDE; GLIMEPIRIDE; GLINIDE DERIVATIVE; GLIPIZIDE; HEMOGLOBIN A1C; INSULIN; METFORMIN; NATEGLINIDE; ORAL ANTIDIABETIC AGENT; REPAGLINIDE; SULFONYLUREA DERIVATIVE; UNCLASSIFIED DRUG; VILDAGLIPTIN; ANTIDIABETIC AGENT; GLYCOSYLATED HEMOGLOBIN;

ARTICLE; DISEASE DURATION; DRUG EFFICACY; DRUG SAFETY; HEMOGLOBIN DETERMINATION; HUMAN; HYPOGLYCEMIA; META ANALYSIS; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; SYSTEMATIC REVIEW; TREATMENT RESPONSE; ADULT; AGED; BLOOD; CHEMICALLY INDUCED; DIABETES MELLITUS, TYPE 2; MIDDLE AGED; STATISTICS AND NUMERICAL DATA; TREATMENT OUTCOME; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; GLICLAZIDE; GLYBURIDE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; METFORMIN; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SULFONYLUREA COMPOUNDS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84943200830     PISSN: 01688227     EISSN: 18728227     Source Type: Journal    
DOI: 10.1016/j.diabres.2015.07.002     Document Type: Article

References (36)

1. Tahrani A.A., Bailey C.J., Del P.S., Barnett A.H. Management of type 2 diabetes: new and future developments in treatment. Lancet 2011, 378:182-197.
2. Thule P.M., Umpierrez G. Sulfonylureas: a new look at old therapy. Curr Diab Rep 2014, 14:473.
3. Global guideline for type 2 diabetes, Diabetes Res Clin Pract, 2014, 104, 1-52.
4. Harper W., Clement M., Goldenberg R., Hanna A., Main A., Retnakaran R., et al. Pharmacologic management of type 2 diabetes. Can J Diabetes 2013, 37(Suppl 1):S61-S68.
5. National Institute for Health and Care Excellence Type 2 diabetes: the management of type 2 diabetes. NICE clinical guideline 87 2014, National Institute for Health and Care Excellence, London, UK, Available at: 〈http://www.nice.org.uk/guidance/cg87/resources/guidance-type-2-diabetes-pdf. 2009〉. (Accessed 25 July 2014).
6. Colagiuri S., Dickinson S., Girgis S., Colagiuri R. National evidence-based guideline for blood glucose control in type 2 diabetes 2014, Diabetes Australia and the NHMRC, Canberra, Australia, Available at: 〈http://www.nhmrc.gov.au/_files_nhmrc/publications/attachments/di19-diabetes-blood-glucose-control.pdf. 2009〉. (Accessed 28 July 2014).
7. Rutten G.E.H.M., De Grauw W.J.C., Nijpels G., Houweling S.T., Van de Laar F.A., Bilo H.J., et al. NHG-Standaard Diabetes mellitus type 2 (derde herziening). Huisarts Wet 2013, 56:512-525. [in Dutch].
8. Inzucchi S.E., Bergenstal R.M., Buse J.B., Diamant M., Ferrannini E., Nauck M., et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2015, 38:140-149.
9. Kahn S.E., Haffner S.M., Heise M.A., Herman W.H., Holman R.R., Jones N.P., et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006, 355:2427-2443.
10. Roumie C.L., Greevy R.A., Grijalva C.G., Hung A.M., Liu X., Murff H.J., et al. Association between intensification of metformin treatment with insulin vs sulfonylureas and cardiovascular events and all-cause mortality among patients with diabetes. JAMA 2014, 311:2288-2296.
11. WHO Model list of essential medicines 2014, World Health Organization, Available at: 〈http://whqlibdoc.who.int/hq/2011/a95053_eng.pdf. 2011〉. 17th edition.
12. WHO Model list of essential medicines 2014, World Health Organization, Available at: 〈http://www.who.int/medicines/publications/essentialmedicines/18th_EML_Final_web_8Jul13.pdf.2013〉. 18th edition.
13. Patel A., MacMahon S., Chalmers J., Neal B., Billot L., Woodward M., et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008, 358:2560-2572.
14. Schernthaner G., Grimaldi A., Di Mario U., Drzewoski J., Kempler P., Kvapil M., et al. GUIDE study: double-blind comparison of once-daily gliclazide MR and glimepiride in type 2 diabetic patients. Eur J Clin Invest 2004, 34:535-542.
15. Schopman J.E., Simon A.C., Hoefnagel S.J., Hoekstra J.B., Scholten R.J., Holleman F. The incidence of mild and severe hypoglycaemia in patients with type 2 diabetes mellitus treated with sulfonylureas: a systematic review and meta-analysis. Diabetes Metab Res Rev 2014, 30:11-22.
16. Landman G.W., de Bock G.H., van Hateren K.J., van Dijk P.R., Groenier K.H., Gans R.O., et al. Safety and efficacy of gliclazide as treatment for type 2 diabetes: a systematic review and meta-analysis of randomized trials. PLoS ONE 2014, 9:e82880.
17. Papanas N., Tziakas D., Chalikias G., Floros D., Trypsianis G., Papadopoulou E., et al. Gliclazide treatment lowers serum ICAM-1 levels in poorly controlled type 2 diabetic patients. Diabetes Metab 2006, 32:344-349.
18. Tessier D., Dawson K., Tetrault J.P., Bravo G., Meneilly G.S. Glibenclamide vs gliclazide in type 2 diabetes of the elderly. Diabet Med 1994, 11:974-980.
19. Kardas P. The DIACOM study (effect of DosIng frequency of oral Antidiabetic agents on the COMpliance and biochemical control of type 2 diabetes). Diabetes Obes Metab 2005, 7:722-728.
20. Pan N.H., Lee T.M., Lin M.S., Huang C.L., Chang N.C. Association of gliclazide and left ventricular mass in type 2 diabetic patients. Diabetes Res Clin Pract 2006, 74:121-128.
21. Filozof C., Gautier J.F. A comparison of efficacy and safety of vildagliptin and gliclazide in combination with metformin in patients with Type 2 diabetes inadequately controlled with metformin alone: a 52-week, randomized study. Diabet Med 2010, 27:318-326.
22. Foley J.E., Sreenan S. Efficacy and safety comparison between the DPP-4 inhibitor vildagliptin and the sulfonylurea gliclazide after two years of monotherapy in drug-naive patients with type 2 diabetes. Horm Metab Res 2009, 41:905-909.
23. Ristic S., Collober-Maugeais C., Pecher E., Cressier F. Comparison of nateglinide and gliclazide in combination with metformin, for treatment of patients with Type 2 diabetes mellitus inadequately controlled on maximum doses of metformin alone. Diabet Med 2006, 23:757-762.
24. Furlong N.J., Hulme S.A., O'Brien S.V., Hardy K.J. Comparison of repaglinide vs. gliclazide in combination with bedtime NPH insulin in patients with Type 2 diabetes inadequately controlled with oral hypoglycaemic agents. Diabet Med 2003, 20:935-941.
25. Inzucchi S.E., Bergenstal R.M., Buse J.B., Diamant M., Ferrannini E., Nauck M., et al. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 2012, 55:1577-1596.
26. Campbell I.W., Howlett H.C. Worldwide experience of metformin as an effective glucose-lowering agent: a meta-analysis. Diabetes Metab Rev 1995, 11(Suppl. 1):S57-S62.
27. Zoungas S., Chalmers J., Kengne A.P., Pillai A., Billot L., de G.B., et al. The efficacy of lowering glycated haemoglobin with a gliclazide modified release-based intensive glucose lowering regimen in the ADVANCE trial. Diabetes Res Clin Pract 2010, 89:126-133.
28. Seino S., Takahashi H., Takahashi T., Shibasaki T. Treating diabetes today: a matter of selectivity of sulphonylureas. Diabetes Obes Metab 2012, 14(Suppl. 1):9-13.
29. Gribble F.M., Reimann F. Differential selectivity of insulin secretagogues: mechanisms, clinical implications, and drug interactions. J Diabetes Complications 2003, 17:11-15.
30. Sadikot S.M., Mogensen C.E. Risk of coronary artery disease associated with initial sulphonylurea treatment of patients with type 2 diabetes: a matched case-control study. Diabetes Res Clin Pract 2008, 82:391-395.
31. Schramm T.K., Gislason G.H., Vaag A., Rasmussen J.N., Folke F., Hansen M.L., et al. Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction: a nationwide study. Eur Heart J 2011, 32:1900-1908.
32. Perkovic V., Heerspink H.L., Chalmers J., Woodward M., Jun M., Li Q., et al. Intensive glucose control improves kidney outcomes in patients with type 2 diabetes. Kidney Int 2013, 83:517-523.
33. KDOQI Clinical practice guideline for diabetes and CKD: 2012 update. Am J Kidney Dis 2012, 60:850-886.
34. Sawada F., Inoguchi T., Tsubouchi H., Sasaki S., Fujii M., Maeda Y., et al. Differential effect of sulfonylureas on production of reactive oxygen species and apoptosis in cultured pancreatic beta-cell line, MIN6. Metabolism 2008, 57:1038-1045.
35. Kimoto K., Suzuki K., Kizaki T., Hitomi Y., Ishida H., Katsuta H., et al. Gliclazide protects pancreatic beta-cells from damage by hydrogen peroxide. Biochem Biophys Res Commun 2003, 303:112-119.
36. Higgins J.P.T., Green S.,(Eds.). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011] 2011, The Cochrane Collaboration, Available from http://www.cochrane-handbook.org.